These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18815935)

  • 21. Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guérin immunotherapy.
    Ahirwar DK; Mandhani A; Dharaskar A; Kesarwani P; Mittal RD
    BJU Int; 2009 Sep; 104(6):867-73. PubMed ID: 19338536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bladder Cancer Chemopreventive Agents: Current Knowledge and Concepts.
    Khajeh NR; Khoyilar C; Wu Y; Spradling K; Zi X; Youssef RF
    Mini Rev Med Chem; 2018; 18(13):1143-1150. PubMed ID: 26975668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological approaches to reducing the risk of prostate cancer.
    Rittmaster RS; Fleshner NE; Thompson IM
    Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arsenic and bladder cancer: observations and suggestions.
    Radosavljević V; Jakovljević B
    J Environ Health; 2008 Oct; 71(3):40-2. PubMed ID: 18990932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondhand smoking, 4-aminobiphenyl, and bladder cancer: two meta-analyses.
    Van Hemelrijck MJ; Michaud DS; Connolly GN; Kabir Z
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1312-20. PubMed ID: 19336562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cancer of the urinary bladder: prognosis of the outcome].
    Zimichev AA; Prianichnikova MB; Maklakov VN
    Urologiia; 2009; (3):52-3. PubMed ID: 19673123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden.
    Malmström PU; Hedelin H; Thomas YK; Thompson GJ; Durrant H; Furniss J
    Scand J Urol Nephrol; 2009; 43(3):192-8. PubMed ID: 19330681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should photodynamic diagnosis be standard practice for bladder cancer?
    Stenzl A; Kruck S
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):697-9. PubMed ID: 19496705
    [No Abstract]   [Full Text] [Related]  

  • 30. Genome-wide association studies in bladder cancer: first results and potential relevance.
    Kiemeney LA; Grotenhuis AJ; Vermeulen SH; Wu X
    Curr Opin Urol; 2009 Sep; 19(5):540-6. PubMed ID: 19553824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [National cancer fund (Koningin Wilhelmina Fonds) and the Houtsmuller-therapy for cancer].
    Mol R
    Ned Tijdschr Geneeskd; 1999 Aug; 143(32):1680. PubMed ID: 10494305
    [No Abstract]   [Full Text] [Related]  

  • 32. Bladder cancer-new approaches.
    Buchanan-Davidson DJ
    Wis Med J; 1980 Aug; 79(8):15-6. PubMed ID: 7415197
    [No Abstract]   [Full Text] [Related]  

  • 33. Intervention strategies for chemoprevention of bladder cancer.
    Sheinfeld J; Herr HW
    J Cell Biochem Suppl; 1992; 16I():173-4. PubMed ID: 1305683
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer.
    Horvath A; Mostafid H
    BJU Int; 2009 Mar; 103(6):726-9. PubMed ID: 19007379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?
    de Bekker-Grob EW; van der Aa MN; Zwarthoff EC; Eijkemans MJ; van Rhijn BW; van der Kwast TH; Steyerberg EW
    BJU Int; 2009 Jul; 104(1):41-7. PubMed ID: 19500328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upper urinary tract recurrence after radical cystectomy for bladder cancer--who is at risk?
    Volkmer BG; Schnoeller T; Kuefer R; Gust K; Finter F; Hautmann RE
    J Urol; 2009 Dec; 182(6):2632-7. PubMed ID: 19836794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Medical and economic cost of bladder cancer in France].
    Legrand G; Guy L
    Rev Prat; 2014 Dec; 64(10):1381. PubMed ID: 25665316
    [No Abstract]   [Full Text] [Related]  

  • 38. Strategies to improve drug delivery in bladder cancer therapy.
    Wirth M; Plattner VE; Gabor F
    Expert Opin Drug Deliv; 2009 Jul; 6(7):727-44. PubMed ID: 19538035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Alternative medicine in cancer. "Promises of cures not validated--severe side-effects].
    Hakimi R
    MMW Fortschr Med; 2004 May; 146(21):17. PubMed ID: 15373077
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic variants in the death receptor 4 gene contribute to susceptibility to bladder cancer.
    ; ; . PubMed ID: 19070628
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.